Last reviewed · How we verify
Vivaglobin
At a glance
| Generic name | Vivaglobin |
|---|---|
| Also known as | Human Normal Immunoglobulin |
| Sponsor | CSL Behring |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of Purified Human Antibodies Administered Subcutaneously to Patients With Multifocal Motor Neuropathy (MMN) (PHASE2)
- Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency (PHASE4)
- Evaluation of Efficacy and Tolerability of Hizentra® (NA)
- Retrospective Chart Review of Subcutaneous IgG Use in Infants
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vivaglobin CI brief — competitive landscape report
- Vivaglobin updates RSS · CI watch RSS
- CSL Behring portfolio CI